Literature DB >> 19084910

Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.

Michael Hopfner, Detlef Schuppan, Hans Scherubl.   

Abstract

The limited efficacy of cytotoxic therapy for advanced biliary tract and gallbladder cancers emphasizes the need for novel and more effective medical treatment options. A better understanding of the specific biological features of these neoplasms led to the development of new targeted therapies, which take the abundant expression of several growth factors and cognate tyrosine kinase receptors into account. This review will briefly summarize the status and future perspectives of antiangiogenic and growth factor receptor-based pharmacological approaches for the treatment of biliary tract and gallbladder cancers. In view of multiple novel targeted approaches, the rationale for innovative therapies, such as combinations of growth factor (receptor)-targeting agents with cytotoxic drugs or with other novel anticancer drugs will be highlighted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19084910      PMCID: PMC2776833          DOI: 10.3748/wjg.14.7021

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  114 in total

1.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Fontanini; S Cuccato; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

Review 2.  Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

Authors:  Jared A Gollob; Scott Wilhelm; Chris Carter; Susan L Kelley
Journal:  Semin Oncol       Date:  2006-08       Impact factor: 4.929

3.  Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.

Authors:  Tomislav Dragovich; Mark Huberman; Daniel D Von Hoff; Eric K Rowinsky; Paul Nadler; Debra Wood; Marta Hamilton; George Hage; Julie Wolf; Amita Patnaik
Journal:  Cancer Chemother Pharmacol       Date:  2006-12-06       Impact factor: 3.333

4.  A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.

Authors:  Robert G Maki; Andrew S Kraft; Kelly Scheu; Jennifer Yamada; Scott Wadler; Cristina R Antonescu; John J Wright; Gary K Schwartz
Journal:  Cancer       Date:  2005-04-01       Impact factor: 6.860

5.  Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.

Authors:  Alexander Huether; Michael Höpfner; Viola Baradari; Detlef Schuppan; Hans Scherübl
Journal:  Biochem Pharmacol       Date:  2007-01-05       Impact factor: 5.858

6.  Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

Authors:  Michael P Fanucchi; Frank V Fossella; Robert Belt; Ronald Natale; Panos Fidias; David P Carbone; Ramaswamy Govindan; Luis E Raez; Francisco Robert; Maria Ribeiro; Wallace Akerley; Karen Kelly; Steven A Limentani; Jeffrey Crawford; Hans-Joachim Reimers; Rita Axelrod; Oscar Kashala; Shihong Sheng; Joan H Schiller
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

7.  Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.

Authors:  Christian Fischer; Bart Jonckx; Massimiliano Mazzone; Serena Zacchigna; Sonja Loges; Lucia Pattarini; Emmanuel Chorianopoulos; Laurens Liesenborghs; Marta Koch; Maria De Mol; Monica Autiero; Sabine Wyns; Stephane Plaisance; Lieve Moons; Nico van Rooijen; Mauro Giacca; Jean-Marie Stassen; Mieke Dewerchin; Desire Collen; Peter Carmeliet
Journal:  Cell       Date:  2007-11-02       Impact factor: 41.582

8.  Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.

Authors:  Michael Höpfner; Alexander Huether; Andreas P Sutter; Viola Baradari; Detlef Schuppan; Hans Scherübl
Journal:  Biochem Pharmacol       Date:  2006-03-10       Impact factor: 5.858

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  4 in total

1.  Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer.

Authors:  Tobias Kiesslich; Christian Mayr; Julia Wachter; Doris Bach; Julia Fuereder; Andrej Wagner; Beate Alinger; Martin Pichler; Pietro Di Fazio; Matthias Ocker; Frieder Berr; Daniel Neureiter
Journal:  Mol Cell Biochem       Date:  2014-07-27       Impact factor: 3.396

2.  Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.

Authors:  Joshua A Roth; Josh J Carlson
Journal:  J Gastrointest Cancer       Date:  2012-06

3.  Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells.

Authors:  Julia Wachter; Daniel Neureiter; Beate Alinger; Martin Pichler; Julia Fuereder; Christian Oberdanner; Pietro Di Fazio; Matthias Ocker; Frieder Berr; Tobias Kiesslich
Journal:  Int J Biol Sci       Date:  2011-11-07       Impact factor: 6.580

4.  Inhibitory effect of isomorellin on cholangiocarcinoma cells via suppression of NF-κB translocation, the phosphorylated p38 MAPK pathway and MMP-2 and uPA expression.

Authors:  Chariya Hahnvajanawong; Thitiporn Sahakulboonyarak; Thidarut Boonmars; Vichai Reutrakul; Anusak Kerdsin; Parichart Boueroy
Journal:  Exp Ther Med       Date:  2020-12-17       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.